For pembrolizumab, patients who were detected a ≥50% PD-L1-expressing tumor cells in NSCLC tissues could be recommended for a first-line therapy, while those who had a ≥1% PD-L1-positive tumor cells are for a second-line treatment. The gene discussed is CD274; the disease is non-small cell lung carcinoma.